تقييم فعالية العلاج بالإيزوتريتنوين عند مرضى العد الشائع في مشفى الأسد الجامعي باللاذقية
Abstract
شملت الدراسة 81 مريضاً (24 ذكراً و 57أنثى ) بأعمار بين15-30 سنة (متوسط 22.5عاماً) يعانون من العد الشائع المتوسط والشديد. تمت معالجتهم بالإيزوتريتنوين بجرعات تراوحت بين 0.5 و0.75 ملغ/كغ/ اليوم ولمدة 4-6 أشهر وجرعة تراكمية بين75- 112.5ملغ /كغ (بمتوسط 93.75 ملغ/كغ) . تمت متابعة المرضى شهرياً لمراقبة التطورات السريرية والآثار الجانبية وإجراء التحاليل المخبرية (الشحوم الثلاثية والكولسترول,وظائف الكبد والكلية,سكر الدم والتعداد العام والصيغة). كانت الاستجابة ممتازة لدى 84% و جيدة لدى 13.6% وضعيفة لدى2.4% معتمدين في ذلك على التحسن السريري . كانت الآثار الجانبية الأكثر شيوعاً هي جفاف الشفتين ومخاطية الأنف , جفاف الجلد والآلام المفصلية والعضلية كما حدث ارتفاع في الشحوم الثلاثية وبدرجة أقل في الكولسترول ووظائف الكبد, ولكن جميعها لم تستدع إيقاف المعالجة. بينت نتائج دراستنا أن العلاج بالإيزوتريتنوين ذو فعالية عالية وآثار جانبية جيدة التحمل إذا أعطي بجرعة تتناسب مع الحالة السريرية في وجود نتائج مخبريه طبيعية قبل بدء المعالجة.
This study included 81 patients ( 24 male and 57 female ), whose ages varied from 15 to 30 years ( mean age 22.5 years) with moderate to severe acne, who were treated with isotretinoin in doses ranging from 0.5 to 0.75 mg/kg / day for a period ranging from 4-6 months, total cumulative dose 75 to 112.5 mg / kg ( mean 93.75 mg /kg). The patients were followed–up monthly for clinical development, side effects and laboratory advers effects .84% of patients achieved excellent response, 13.6% good and 2.4%weak. The main side effects are dryness of lips and nasal mucosa, arthralgia / myalgia and mild to moderate elevation in lipids and liver enzyme levels. According to our results, isotretinoin is effective and its side effects can be tolerated if we give the dose suitable to clinical evidence to the patient who has normal laboratory results.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors retain the copyright and grant the right to publish in the magazine for the first time with the transfer of the commercial right to Tishreen University Journal for Research and Scientific Studies - Health Sciences Series
Under a CC BY- NC-SA 04 license that allows others to share the work with of the work's authorship and initial publication in this journal. Authors can use a copy of their articles in their scientific activity, and on their scientific websites, provided that the place of publication is indicted in Tishreen University Journal for Research and Scientific Studies - Health Sciences Series . The Readers have the right to send, print and subscribe to the initial version of the article, and the title of Tishreen University Journal for Research and Scientific Studies - Health Sciences Series Publisher
journal uses a CC BY-NC-SA license which mean
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.